Search

Author/Creator Havunen, R.

1. 50P Enhancing TIL and NK cells adoptive therapies with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer. (December 2022)

Authors:
Quixabeira, D.C.A.; Pakola, S.; Jirovec, E.; Basnet, S.; Santos, J.M.; Kudling, T.; Clubb, J.; Haybout, L.; Arias, V.; Grönberg-Vähä-Koskela, S.; Havunen, R.; Cervera-Carrascon, V.; Pasanen, A.; Tapper, J.; Kanerva, A.; Hemminki, A.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 51P Immunological analysis of blood from patients with solid tumors treated with TILT-123: An oncolytic adenovirus encoding for tumor necrosis factor alpha (TNFa) and interleukin 2 (IL-2). (December 2022)

Authors:
Pakola, S.; Santos, J.M.; Cervera-Carrascon, V.; Kistler, C.; Sorsa, S.; Havunen, R.; Hemminki, A.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 52P MUC1 targeted immunotherapy with an oncolytic adenovirus coding for a bispecific T cell engager. (December 2022)

Authors:
Basnet, S.; Santos, J.M.; Quixabeira, D.C.A.; Clubb, J.; Grönberg-Vähä-Koskela, S.; Pakola, S.; Kudling, T.; Heiniö, C.; Havunen, R.; Cervera-Carrascon, V.; Sorsa, S.; Anttila, M.; Kanerva, A.; Hemminki, A.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗